Literature DB >> 7789400

Nitroimidazoles and imaging hypoxia.

A Nunn1, K Linder, H W Strauss.   

Abstract

Decreased tissue oxygen tension is a component of many diseases. Although hypoxia can be secondary to a low inspired pO2 or a variety of lung disorders, the commonest cause is ischemia due to an oxygen demand greater than the local oxygen supply. In tumors, low tissue pO2 is often observed, most often due to a blood supply inadequate to meet the tumor's demands. Hypoxic tumor tissue is associated with increased resistance to therapy. In the heart tissue hypoxia is often observed in persistent low-flow states, such as hibernating myocardium. In patients with stroke, hypoxia has been associated with the penumbral region, where an intervention could preserve function. Despite the potential importance of oxygen levels in tissue, difficulty in making this measurement in vivo has limited its role in clinical decision making. A class of compounds known to undergo different intracellular metabolism depending on the availability of oxygen in tissue, the nitroimidazoles, have been advocated for imaging hypoxic tissue. When a nitroimidazole enters a viable cell the molecule undergoes a single electron reduction, to form a potentially reactive species. In the presence of normal oxygen levels the molecule is immediately reoxidized. This futile shuttling takes place for some time, before the molecule diffuses out of the cell. In hypoxic tissue the low oxygen concentration is not able to effectively compete to reoxidize the molecule and further reduction appears to take place, culminating in the association of the reduced nitroimidazole with various intracellular components. The association is not irreversible, since these agents clear from hypoxic tissue over time. Initial development of nitroimidazoles for in vivo imaging used radiohalogenated derivatives of misonidazole, such as fluoromisonidazole, some of which have recently been employed in patients. Two major problems with fluoromisonidazole are its relatively low concentration within the lesion and the need to wait several hours to permit clearance of the agent from the normoxic background tissue (contrast between lesion and background typically < 2:1 at about 90 min after injection). Even with high-resolution positron emission tomographic imaging, this combination of circumstances makes successful evaluation of hypoxic lesions a challenge.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789400     DOI: 10.1007/bf01081524

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  70 in total

1.  Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy.

Authors:  R A Gatenby; H B Kessler; J S Rosenblum; L R Coia; P J Moldofsky; W H Hartz; G J Broder
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-05       Impact factor: 7.038

Review 2.  The metabolic activation of nitroheterocyclic therapeutic agents.

Authors:  G L Kedderis; G T Miwa
Journal:  Drug Metab Rev       Date:  1988       Impact factor: 4.518

3.  The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.

Authors:  R A White; P Workman; J M Brown
Journal:  Radiat Res       Date:  1980-12       Impact factor: 2.841

4.  Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium.

Authors:  M E Shelton; C S Dence; D R Hwang; M J Welch; S R Bergmann
Journal:  J Nucl Med       Date:  1989-03       Impact factor: 10.057

5.  Imaging ischemic tissue at risk of infarction during stroke.

Authors:  R J Di Rocco; B L Kuczynski; J P Pirro; A Bauer; K E Linder; K Ramalingam; J E Cyr; Y W Chan; N Raju; R K Narra
Journal:  J Cereb Blood Flow Metab       Date:  1993-09       Impact factor: 6.200

6.  Structure-pharmacokinetic relationships for misonidazole analogues in mice.

Authors:  P Workman; J M Brown
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  The synthesis and in vitro evaluation of a 99mtechnetium-nitroimidazole complex based on a bis(amine-phenol) ligand: comparison to BMS-181321.

Authors:  K Ramalingam; N Raju; P Nanjappan; K E Linder; J Pirro; W Zeng; W Rumsey; D P Nowotnik; A D Nunn
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

8.  The oxygen dependence of mitochondrial oxidative phosphorylation measured by a new optical method for measuring oxygen concentration.

Authors:  D F Wilson; W L Rumsey; T J Green; J M Vanderkooi
Journal:  J Biol Chem       Date:  1988-02-25       Impact factor: 5.157

9.  Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia.

Authors:  G V Martin; J E Biskupiak; J H Caldwell; J S Rasey; K A Krohn
Journal:  J Nucl Med       Date:  1993-06       Impact factor: 10.057

10.  A marker for hypoxic cells in tumours with potential clinical applicability.

Authors:  J D Chapman; A J Franko; J Sharplin
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

View more
  76 in total

1.  Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.

Authors:  Nilesh K Wagh; Zhengyuan Zhou; Sunny M Ogbomo; Wen Shi; Susan K Brusnahan; Jered C Garrison
Journal:  Bioconjug Chem       Date:  2012-02-16       Impact factor: 4.774

2.  A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).

Authors:  Satish K Chitneni; Gerald T Bida; Mark W Dewhirst; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2012-06-22       Impact factor: 2.408

Review 3.  Potential Role of PET/MRI for Imaging Metastatic Lymph Nodes in Head and Neck Cancer.

Authors:  Sungheon Gene Kim; Kent Friedman; Sohil Patel; Mari Hagiwara
Journal:  AJR Am J Roentgenol       Date:  2016-05-10       Impact factor: 3.959

Review 4.  Nuclear medicine at the crossroads.

Authors:  H W Strauss
Journal:  Eur J Nucl Med       Date:  1996-06

5.  Dynamic oxygenation measurements using a phosphorescent coating within a mammary window chamber mouse model.

Authors:  Rachel Schafer; Arthur F Gmitro
Journal:  Biomed Opt Express       Date:  2015-01-29       Impact factor: 3.732

Review 6.  An overview of the developments and potential applications of 68Ga-labelled PET/CT hypoxia imaging.

Authors:  Philippa L Bresser; Mariza Vorster; Mike M Sathekge
Journal:  Ann Nucl Med       Date:  2021-01-05       Impact factor: 2.668

Review 7.  Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.

Authors:  J P Holland; J S Lewis; F Dehdashti
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

8.  Imaging of hypoxic-ischemic penumbra with (18)F-fluoromisonidazole PET/CT and measurement of related cerebral metabolism in aneurysmal subarachnoid hemorrhage.

Authors:  Asita S Sarrafzadeh; Alexandra Nagel; Marcus Czabanka; Timm Denecke; Peter Vajkoczy; Michail Plotkin
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-23       Impact factor: 6.200

9.  Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.

Authors:  Carmen S Dence; Datta E Ponde; Michael J Welch; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

10.  1,2-Bis[2-(2-nitro-1H-imidazol-1-yl)eth-oxy]ethane.

Authors:  Shu-Xian Li; Lin Zhu; Hua-Min Li; Hoong-Kun Fun; Suchada Chantrapromma
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.